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Abstract 
Aims: Nipple-sparing mastectomy (NSM) is a surgical procedure for patients with breast cancer without 
nipple-areolar complex (NAC) involvement. Robotic NSM (RNSM) with immediate breast reconstruction has 
been recently introduced; however, reports regarding RNSM are still lacking. Therefore, this study aimed to 
evaluate the postoperative assessment with a focus on postoperative pain of RNSM with prepectoral 
immediate prosthesis breast reconstruction (IPBR) compared with conventional NSM (CNSM) in patients with 
breast cancer without NAC invasion. 
Methods: This retrospective study included 81 patients who underwent RNSM (n = 40) or CNSM (n = 41) 
with prepectoral IPBR using direct-to-implant or tissue expander between January 2018 and June 2020. The 
primary endpoint was to compare postoperative pain intensity based on a numerical rating scale (NRS). The 
secondary endpoint was to evaluate the postoperative recovery profile, including postoperative 
nausea/vomiting (PONV) and complications. 
Results: A statistical difference was observed in the resting NRS scores at 0−6 postoperative hours between 
the RNSM and CNSM groups (3.2 ± 1.5 versus 4.2 ± 1.6, respectively; Bonferroni corrected P = 0.005), 
however, no difference was shown at other time periods. Also, no between-group difference was found in the 
NRS scores for acting pain within 48 postoperative hours and the number of patients requiring additional 
analgesics. 
Conclusions: Despite a statistical difference in the resting NRS scores during the early postoperative phase, 
the absence of any significant difference in the requirement of additional analgesics between the groups 
suggested that RNSM does not significantly attenuate postoperative pain intensity. 
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Introduction 
Nipple-sparing mastectomy (NSM) is a surgical 
procedure performed in patients with breast cancer 
without the involvement of the nipple-areolar 
complex (NAC), to improve the cosmetic outcome 
and quality of life in women with early breast cancer 
or germline BRCA1/2 mutation. In NSM, the skin 
envelope and NAC are preserved, and the glandular 








immediate breast reconstruction (IBR) using 
autologous tissue and/or implants [1]. Preservation of 
the NAC enhances the esthetic outcome and patient 
satisfaction without compromising oncologic 
safety [2]. However, dissecting and removing breast 
tissue through limited incisions is technically 
challenging. Some NSM incisions leave visible scars 
on the breast dome and cause distortion or 
malposition of the NAC. NAC-related necrosis also 
remains a major NSM complication [3,4]. 
Robotic NSM (RNSM) with IBR was first 
described by Toesca et al. [5] in October 2015 and has 
substantially contributed to overcoming the 
challenges of conventional NSM (CNSM) [6]. A high- 
resolution ten-fold magnifying three-dimensional 
camera allows accurate visualization and better access 
to the surgical planes, which enables RNSM with IBR 
through a small axillary incision. The flexibility and 
sophisticated motion of robotic surgical systems 
increase the surgical accuracy in a limited space [3,7]. 
RNSM with a 2.5–6-cm axillary incision has excellent 
patient satisfaction and cosmetic results, considering 
the absence of scarring in the anterior breast. RNSM 
has low ischemic NAC complication rates, which may 
be attributed to the remote incision from the NAC and 
the vascular advantage allowed by sparing small 
vessels responsible for vascular supply to the 
nipple [7,8]. 
Despite several limitations, including a longer 
duration of operation, higher cost, and lack of 
research on the long-term oncological outcomes, 
RNSM with IBR has been increasingly used 
worldwide given its definite advantage with respect 
to esthetics [6,8-11]. However, there are few studies 
on the postoperative outcomes of RNSM with IBR [8]. 
Thus, this study aimed to evaluate the 
postoperative parameters, particularly postoperative 
pain, of RNSM with prepectoral immediate prosthesis 
breast reconstruction (IPBR) using direct-to-implant 
(DTI) or tissue expander, compared with CNSM in 
patients with breast cancer without NAC invasion. 
Materials and methods 
Patient population 
We identified the records of 94 consecutive 
patients with breast cancer who underwent unilateral 
RNSM or CNSM with prepectoral IPBR using DTI or 
tissue expander between January 2018 and June 2020 
at Severance Hospital, Seoul, Korea. Three patients 
who had previously undergone breast surgery, seven 
patients who underwent other simultaneous 
surgeries, and four patients who were not 
administered intravenous patient-controlled 
analgesia (IV-PCA) for postoperative pain control 
were excluded. Consequently, 81 patients who 
underwent RNSM (n = 40) and CNSM (n = 41) were 
analyzed (Figure 1). 
Surgical procedures 
RNSM 
Detailed procedures for RNSM have been 
previously described [3,9-11]. Briefly, a 2.5-6-cm 
linear mid-axillary incision was made below the 
axillary fossa. The ipsilateral arm was straightened 
with internal rotation and abduction and fixed above 
the head. A sentinel lymph node biopsy was 
performed through the incision; moreover, the 
working space beneath the skin flap or 
retromammary space was manually developed. 
Subsequently, a single-port device was inserted 
through the same incision for the gas-inflated 
technique and the robotic surgical system was 
docked. After carbon dioxide gas insufflation with 8–
10 mmHg for surgical field expander, the skin flap 
and/or retromammary space were dissected using the 
robotic surgical system. During the 
mastectomy, the sub-NAC tissue was 
resected to evaluate tumor cell 
involvement in a frozen section. Finally, 
the entire breast parenchyma was 
retrieved through the same incision, and 
prepectoral IPBR using DTI or tissue 
expander was performed by the plastic 
surgeons [3,10].
CNSM 
Various skin incisions such as 
inframammary fold incision, radial 
incision, and/or periareolar/ 
circumareolar incision were made. The 
skin flaps were developed along the 
superficial fascia superior to the lower 
 
 
Figure 1. Consort flow diagram. NSM, nipple-sparing mastectomy; IPBR, immediate prosthesis breast 
reconstruction; PCA, patient-controlled analgesia; RNSM, robotic nipple-sparing mastectomy; CNSM, 
conventional nipple-sparing mastectomy. 




clavicular border, medial to the ipsilateral sternal 
border, inferior to the rectus sheath, and posterior to 
the anterior latissimus dorsi muscle border. The entire 
breast gland was dissected from the pectoralis major 
muscle, including the pectoralis fascia. A frozen 
section for the sub-NAC tissue was intraoperatively 
obtained. Through the same incision, sentinel lymph 
node biopsy using navigator and/or axillary lymph 
node dissection was performed. After the 
mastectomy, prepectoral IPBR using tissue expander 
or implant was performed by the plastic 
surgeons [12]. 
IPBR 
IPBR after mastectomy was performed using DTI 
or tissue expander in the prepectoral space. The 
implant or tissue expander was completely wrapped 
with acellular dermal matrix (ADM) before insertion. 
Patients undergoing autologous reconstruction or 
subpectoral prosthesis were excluded from the 
current study. 
Anesthetic procedures 
General anesthesia was administered following 
our institution’s conventional protocol. After the 
patient arrived in the operating room, all devices 
monitoring oxygen saturation, electrocardiography, 
noninvasive arterial blood pressure, and bispectral 
index (BIS), were utilized to evaluate the patient. 
Intravenous (IV) injection of 0.1 mg glycopyrrolate 
was administered as premedication. Subsequently, 
anesthesia was induced using propofol (1-1.5 mg/kg), 
rocuronium (0.6 mg/kg), and remifentanil (0.05-0.1 
μg/kg). Mechanical ventilation was initiated with an 
inspiration to expiration (I:E) ratio of 1:2, positive 
end-expiratory pressure of 5 cmH2O, tidal volume of 
6-8 ml/kg, and respiratory rate of 8–14 frequency/ 
min to maintain an end-tidal carbon dioxide of 35-42 
mmHg. Anesthesia was maintained using sevoflurane 
or desflurane (0.8-1 age-adjusted minimum alveolar 
concentration) and remifentanil at 0.03–0.1 µg/kg/ 
min. To maintain a constant anesthetic depth, the BIS 
was continuously monitored, with a target range of 
40-60. 
Postoperative pain management 
Prior to the end of the surgery, 1 μg/kg of 
fentanyl (Hana Pharm, Seoul, Korea) and 0.3 mg of 
ramosetron (Nasea®, Astellas Pharma Korea, Seoul, 
Korea) were concurrently administered to relieve 
postoperative pain and nausea/vomiting, 
respectively. All patients received an IV-PCA device 
(Anapa plus; E-HWA Biomedics, Seoul, Korea), 
programmed to 2 mL/h for background infusion, a 
demand volume of 0.5 mL, lock-out interval of 15 
minutes, with a total volume of 100 mL. The PCA 
regimen comprised 15 ± 2 µg/kg of fentanyl and 0.3 
mg of ramosetron, which were mixed with normal 
saline to achieve a total volume of 100 mL. 
Additionally, patients in both groups received 1 g IV 
paracetamol (profa®, Dai han Pharm, Seoul, Korea) at 
8-h intervals for 5 days, and one Mypol® tablet 
(codeine phosphate 10 mg plus ibuprofen 200 mg, 
Sung-won Adcock Pharm, Seoul, Korea) at 8-h 
intervals until discharge. 
Postoperative pain assessment 
Data regarding postoperative pain was obtained 
from an electronic medical database, which was 
recorded by a PCA management team comprising 
two qualified nurses. Resting pain was defined as 
pain while at rest or staying still; acting pain was 
defined as pain during movement, posture change, or 
coughing. All eligible patients were informed on how 
to rate their pain intensity using the numerical rating 
scale (NRS; 0, no pain; 10, worst pain possible) in the 
pre-anesthetic room [13]. After the patients were 
moved to the post-anesthetic care unit (PACU) and 
had emerged from anesthesia, the recovery nurses 
assessed their NRS scores. The patients were 
instructed about the use of the PCA device, and were 
encouraged to push the button whenever they 
experienced pain. In patients who experienced 
sustained pain with a resting NRS score ≥4, 50 µg IV 
fentanyl was administered as an additional rescue 
analgesic. After the patients were transferred to the 
admission room, postoperative resting and acting 
NRS score assessments were performed at 0−6, 6−24, 
and 24-48 postoperative hours. In patients who 
suffered from the prolonged pain with a resting NRS 
score of ≥4 in the admission room, 50 mg tridol 
(Tramadol HCL®, Yuhan. Co., Seoul, Korea) was 
administered as a rescue analgesic. 
Postoperative nausea and vomiting (PONV) 
and complications 
Postoperative management during 
hospitalization was left at the discretion of the Yonsei 
Breast Cancer Center team. PONV was assessed on a 
4-point NRS (0-3; 0 = none, 1 = mild, 2 = moderate, 3 = 
severe). All patients received 0.3 mg IV ramostron at 
24-h intervals for 3 days. Rescue antiemetics were 
administered when severe nausea or vomiting 
developed, or upon request from the patients. 
Metoclopramide (Macperan®, Dong Wha Pharm. Co., 
Ltd., Seoul, Korea) 10 mg was administered as a 
first-line rescue antiemetic. Patients with persistent 
and refractory PONV received 0.3 mg IV ramosetron. 
The incidence of postoperative complications was 
assessed for up to 90 postoperative days. Major 
complications included implant loss, nipple necrosis, 




and/or mastectomy skin flap necrosis requiring 
surgical treatment. Mild complications included 
seroma, hematoma, minor infection, wound 
dehiscence, and nipple or skin flap necrosis with 
conservative management. 
Data collection 
Demographic and preoperative characteristics, 
including age, body mass index (BMI), American 
Society of Anesthesiologists physical status, smoking 
history, menopause status, family history of breast 
cancer, and neoadjuvant chemotherapy were 
assessed. Regarding perioperative and surgical 
characteristics, duration of anesthesia and operation, 
blood loss, dose of remifentanil administered, dose of 
fentanyl combined with PCA, surgical incision length, 
mastectomy specimen weight, location, 
reconstruction type, reconstruction implant volume, 
and adjuvant treatment were assessed. Further, 
pathologic variables were collected. Additionally, 
postoperative profiles, including postoperative 
hospital stay, PONV, and complications were 
evaluated. Postoperative NRS scores to determine the 
maximum resting and acting pain were assessed in 
the PACU at 0-6, 6-24, and 24-48 postoperative hours. 
Furthermore, the number of patients requiring 
additional analgesics for up to postoperative 48 hours 
were assessed. 
Statistical analysis 
Continuous variables are presented as mean ± 
standard deviation (SD) while categorical variables 
are presented as the number of patients (percentage). 
Between-group differences in the continuous and 
categorical variables were analyzed using the 
Student’s t-test and the Chi-square test/Fisher’s exact 
test, respectively. To determine the group and time 
effects for repeated-measure continuous and 
categorical variables, linear mixed model analysis and 
generalized estimating equations were performed, 
respectively. Bonferroni correction was applied to 
adjust for multiple comparisons in post-hoc analyses. 
P < 0.05 was considered statistically significant. All 
analyses were conducted using SAS version 9.4 (Cary, 
NC). 
Results 
Table 1 demonstrates the clinicopathologic 
factors of the patients selected for this retrospective 
analysis. The average BMI in the RNSM group was 
lower than that in the CNSM group by 1.7 kg/m2 (22.2 
± 3.5 vs. 23.9 ± 3.6 kg/m2, P = 0.030), and no 
between-group differences were observed regarding 
other variables. Table 2 summarizes the 
intraoperative and surgical variables. Duration of 
anesthesia and operation were significantly longer in 
the RNSM group than in the CNSM group (both P < 
0.001). There was no between-group difference in the 
dose of fentanyl used for PCA (15.0 ± 1.8 µg/kg, 
RNSM group; 14.6 ± 1.6 µg/kg, CNSM group). The 
surgical incision length in the RNSM group (4.4 ± 0.7 
cm) was significantly shorter than that in the CNSM 
group (8.8 ± 2.2 cm; P <0.001). 
 
Table 1. Clinicopathologic factors of patients selected for the 
analysis 
 RNSM (n = 40) CNSM (n = 41) P value 
Patients characteristics    
Age, years 46 ± 8 49 ± 10 0.177 
Body mass index, kg/m2 22.2 ± 3.5 23.9 ± 3.6 0.030* 
ASA physical status   0.381 
I 19 (48%) 16 (39%)  
II 19 (48%) 19 (46%)  
III 2 (5%) 6 (15%)  
Smoking history   0.836 
Non-smoker 37 (93%) 36 (88%)  
Ex-smoker 2 (5%) 4 (10%)  
Current-smoker 1 (2%) 1 (2%)  
Menopause status   0.268 
Premenopausal 28 (70%) 25 (64%)  
Postmenopausal 10 (25%) 14 (36%)  
Perimenopausal 2 (5%) 0 (0%)  
Neoadjuvant chemotherapy 5 (13%) 11 (27%) 0.105 
Pathologic characteristics    
Pathologic tumor size, cm 1.6 ± 1.3 1.8 ± 1.1 0.420 
Multicentric/multifocal lesion 19 (48%) 16 (39%) 0.441 
Lymph node procedure   0.712 
SLNB only 37 (93%) 36 (88%)  
SLNB then ALND 3 (8%) 5 (12%)  
Pathologic staging, pT   0.283 
Tis 6 (15%) 9 (22%)  
T1 28 (70%) 21 (51%)  
T2 6 (15%) 9 (22%)  
T0 0 (0%) 2 (5%)  
Pathologic staging, pN   0.432 
N0 37 (93%) 36 (88%)  
N1 2 (5%) 5 (12%)  
N2 0 (0%) 0 (0%)  
N3 1 (3%) 0 (0%)  
Histopathologic grade   0.300 
G1 13 (33%) 10 (25%)  
G2 23 (57%) 21 (53%)  
G3 4 (10%) 9 (23%)  
HER2 status   0.173 
Negative 28 (70%) 24 (59%)  
Positive 11 (28%) 11 (27%)  
Not available 1 (3%) 6 (15%)  
Estrogen receptor status   0.446 
Negative 7 (18%) 10 (24%)  
Positive 33 (83%) 31 (76%)  
Progesterone receptor status   0.352 
Negative 9 (23%) 13 (32%)  
Positive 31 (78%) 28 (68%)  
Ki 67   0.223 
Low (<14%) 20 (50%) 26 (63%)  
High (≥14%) 20 (50%) 15 (37%)  
Notes: Data are presented as mean ± standard deviation or number of patients 
(proportion). *P <0.05. 
Abbreviation: RNSM, robotic nipple sparing mastectomy; CNSM, conventional 
nipple-sparing mastectomy; ASA, American Society of Anesthesiologists; SLNB, 
sentinel lymph node biopsy; ALNB, axillary lymph node biopsy; HER2, human 
epidermal growth factor receptor 2; Tis, carcinoma in situ. 




Table 2. Perioperative and surgical characteristics 
 RNSM (n = 40) CNSM (n = 41) P value 
Anesthesia time, min 331 ± 74 241 ± 43 <0.001* 
Operation time, min 279 ± 63 207 ± 46 <0.001* 
Blood loss   0.057 
≤100 mL 34 (85%) 40 (98%)  
>100 mL 6 (15%) 1 (2%)  
Administered remifentanil (µg/kg/hr) 0.047 ± 0.010 0.047 ± 0.010 0.998 
Fentanyl amounts mixed in PCA 
(µg/kg) 
15.0 ± 1.8 14.6 ± 1.6 0.221 
Incision length, cm 4.4 ± 0.7 8.8 ± 2.2 <0.001* 
Specimen weight, g 388.7 ± 169.5 421.4 ± 176.0 0.400 
Location   0.144 
Right 25 (63%) 19 (46%)  
Left 15 (38%) 22 (54%)  
Type of reconstruction   0.195 
Direct-to-implant 32 (80%) 37 (90%)  
Tissue expander insertion 8 (20%) 4 (10%)  
Volume of reconstruction implant, mL 366 ± 111 357 ± 110 0.718 
Adjuvant treatment     
Radiation therapy 5 (13%) 8 (20%) 0.390 
Chemotherapy 10 (25%) 12 (29%) 0.666 
Endocrine therapy 32 (80%) 26 (67%) 0.180 
Notes: Data are presented as mean ± standard deviation or number of patients 
(proportion). *P <0.05. 
Abbreviation: RNSM, robotic nipple-sparing mastectomy; CNSM, conventional 
nipple-sparing mastectomy; PCA, patient-controlled analgesia. 
 
 
Figure 2. Resting (A) and acting (B) pain intensity in the RNSM and CNSM groups 
during 48 postoperative hours. NRS, numerical rating scale; RNSM, robotic 
nipple-sparing mastectomy; CNSM, conventional nipple-sparing mastectomy; PACU, 
post-anesthesia care unit. *Bonferroni corrected P = 0.005 compared with CNSM. 
 
Figure 2 presents the resting and acting pain 
intensity. The linear mixed model analysis revealed 
significant between-group differences in the resting 
NRS score (P Group x Time = 0.007) (Figure 2A). After the 
post-hoc analysis, a statistical difference was observed 
in the resting NRS scores at 0-6 postoperative hours 
between the RNSM and CNSM groups (3.2 ± 1.5 
versus 4.2 ± 1.6, respectively; Bonferroni corrected P = 
0.005); however, no difference was shown at other 
time periods (PACU, 6-24, and 24-48 postoperative 
hours). Additionally, there was no between-group 
difference in the NRS scores for acting pain up to 48 
postoperative hours (Figure 2B), and in the number of 
patients requiring additional analgesics (Figure 3). 
 
 
Figure 3. Number of patients who required additional analgesics during the first 48 
postoperative hours. RNSM, robotic nipple sparing mastectomy; CNSM, 
conventional nipple sparing mastectomy; PACU, post-anesthesia care unit. 
Table 3. Postoperative profile 
 RNSM (n = 40) CNSM (n = 41) P value 
Postoperative hospital stays, days 9.2 ± 2.7 7.1 ± 2.0 <0.001* 
Postoperative hospital stays, days 
(recent 20 cases) 
7.8 ± 1.9 7.0 ± 2.2 0.252 
Nausea (severe/moderate/mild/none)   
At PACU 6/2/0/32 5/2/0/34 0.906 
0-6 hours 8/5/1/26 10/7/2/22 0.747 
6-24 hours 4/6/5/25 7/4/1/29 0.262 
Vomiting    
At PACU 2 (5%) 3 (7%) >0.999 
0-6 hours 6 (15%) 12 (29%) 0.123 
6-24 hours 2 (5%) 6 (15%) 0.264 
Postoperative complication    
Seroma 2 (5%) 2 (5%) >0.999 
Hematoma 0 (0%) 2 (5%) 0.494 
Wound dehiscence 1 (3%) 4 (10%) 0.359 
Infection 3 (8%) 3 (7%) >0.999 
Nipple necrosis    
Surgical Tx 0 (0%) 1 (2%) >0.999 
Conservative Tx 5 (13%) 5 (12%) >0.999 
Mastectomy skin flap necrosis    
Surgical Tx 2 (5%) 6 (15%) 0.264 
Conservative Tx 1 (3%) 1 (2%) >0.999 
Notes: Data are presented as mean ± standard deviation or number of patients 
(proportion). *P <0.05. 
Abbreviation: RNSM, robotic nipple-sparing mastectomy; CNSM, conventional 
nipple-sparing mastectomy; PACU, post-anesthesia care unit; Tx, treatment. 
 
 
Table 3 presents the postoperative recovery 
profiles, including PONV and postoperative 
complications. In the analysis of the last 20 cases in 
each group, no difference was observed between the 
two groups in the average length of postoperative 
hospital stay (P = 0.252). Moreover, there was no 
between-group difference in the number of patients 
who had PONV and complications up to 90 
postoperative days. No patient had unrecoverable 
complications. 





This study analyzed postoperative pain in 
RNSM with prepectoral IPBR compared with CNSM, 
which showed a statistical difference in resting NRS 
scores between the two groups; however, the 
difference was transient and observed only during 0-6 
postoperative hours. Further, no between-group 
difference was observed in the number of patients 
requiring additional analgesics, the incidence of 
PONV, and postoperative complications. 
Approximately 25%-60% of patients present 
with persistent pain after breast cancer surgery, which 
is a major clinical issue [14,15]. It leads to chronic pain 
in a substantial number of patients, which decreases 
the quality of life and deteriorates their physical 
functions [16,17]. There may be multifactorial risk 
factors for this pain, including patient-related and 
treatment-related risk factors, such as the type of 
procedure performed [15]. Therefore, there is a need 
for surgical approaches that alleviate postoperative 
pain to improve the postoperative outcome in 
patients. Minimally invasive robotic approaches have 
been demonstrated to reduce postoperative pain for 
various surgeries [18,19]. Given the rapid expander of 
robotic approaches for breast procedures, there have 
been several reports regarding the feasibility and 
advantages of RNSM with IBR [4-8]. However, no 
evaluation regarding the postoperative pain 
assessment in RNSM compared with CNSM has been 
performed. 
In this study, a statistical difference was 
observed in the resting NRS scores at 0−6 
postoperative hours between the RNSM and CNSM 
groups (3.2 ± 1.5 versus 4.2 ± 1.6, respectively; 
Bonferroni corrected P = 0.005); however, which 
might be subjective depending on the patients, and 
difference was transient and observed only during the 
0-6 postoperative hours. Additionally, no difference 
was observed at other time periods (PACU, 6-24, and 
24-48 postoperative hours), which may suggest that 
some degree of pain control was achieved through 
routine IV PCA. This might negate the minor 
difference in pain associated with skin flap incision 
and length (4.4 cm versus 8.8 cm; ~4.4-cm difference) 
between the two types of surgeries. To control for 
other factors that may affect pain intensity, we only 
included patients who underwent unilateral NSM and 
prepectoral IPBR, which involves wrapping the 
prosthesis in a material such as ADM and placing it 
behind the skin flap. This approach is less invasive, 
more cosmetically effective, and less painful since 
pectoralis major muscle (PMM) dissection is not 
required. In contrast, subpectoral IPBR involves 
placement of the prosthetic device in the submuscular 
pocket behind the PMM [20,21]. However, no 
difference was observed between the two groups 
regarding acting pain intensity during 48 
postoperative hours and the number of patients who 
required additional analgesics. 
Between-group differences were observed in the 
demographics in terms of incision length, BMI, 
operation time, and hospital stay. BMI in the RNSM 
group was lower than that in the CNSM group by 1.7 
kg/m2 (22.2 ± 3.5 vs. 23.9 ± 3.6 kg/m2, respectively), 
which was statistically, though not clinically, different 
between the groups, since there was no 
between-group difference in the breast volume. A 
smaller incision length, longer duration of operation, 
and higher medical cost were specific RNSM features, 
which is consistent with the findings of a previous 
study [3,8]. In this study, the length of hospital stay in 
the RNSM group was 2 days longer than that in the 
CNSM group, which might be attributed to the 
preference of both patients and plastic surgeons for a 
slightly longer hospital stay in the early phase of 
RNSM to prioritize safety in an innovative surgical 
procedure. However, after the initial experience in 
RNSM, this difference in the length of hospital stay 
disappeared, as observed in the results of the analysis 
of length of hospital stay among the last 20 patients in 
each group (7.8 ± 1.9 versus 7.0 ± 2.2 days, P = 0.252). 
Additionally, there was no between-group difference 
in the number of patients who presented with PONV. 
With regard to postoperative complications, 
there was no difference between the two groups in the 
present study, which was consistent with the findings 
of Lai HW et al. [8]. However, in a recent report by 
Lee et al., RNSM showed significantly lower 
postoperative nipple necrosis and high-grade 
postoperative complications rates, [22] a discrepancy 
that appears to be due to a difference in the study 
population. The previous report by Lee et al. from our 
institution included >200 cases of robotic and 
conventional mastectomy, including autologous 
breast reconstruction, whereas the current study 
included only NSM with implant-based 
reconstruction. All patients who experienced 
complications in this study recovered completely 
without any other severe complications. 
To our knowledge, this is the first study 
comparing RNSM versus CNSM with a focus on 
postoperative pain. However, this study has several 
limitations, including its retrospective nature, small 
sample size, and missing information, such as the 
total consumed dose of analgesics per time unit, 
frequency and dose of bolus on demand, and chronic 
pain assessment after 48 hours. We could only 
evaluate the analgesia quality by comparing the pain 
intensity based on the NRS scores and the number of 
patients requiring rescue analgesic as a surrogate. To 




overcome those limitations and clarify the findings of 
this study, further large-scale prospective trials are 
needed. Nonetheless, our findings are clinically 
significant to the existing literature. 
Conclusions 
Despite a statistical difference in the resting NRS 
scores during the early postoperative phase, the 
absence of any significant difference in the 
requirement of additional analgesics between the 
groups suggested that RNSM does not significantly 
attenuate postoperative pain intensity in patients with 
breast cancer without NAC invasion. Further 
prospective trials are needed to clarify this. 
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